GlassScriptPhysician profile
Rani Kulkarni
NPI 1932362365
$3,496.52
in general payments reported to CMS, 2019-2025
26 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $377 · 2021: $417 · 2022: $571 · 2023: $500 · 2024: $234 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $626.64 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $548.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $408.17 | 2019-2023 | |
| Dexcom, INC. | $372.91 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.41 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $146.19 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $140.43 | 2019 | |
| Beta Bionics, INC. | $118.47 | 2024 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $116.83 | 2019 | |
| Xeris Pharmaceuticals, INC. | $105.95 | 2022 | |
| Medtronic, INC. | $103.76 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $101.56 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $100.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $63.65 | 2019-2020 | |
| Becton, Dickinson and Company | $58.83 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $47.75 | 2019-2023 | Omnipod |
| Ipsen Biopharmaceuticals, INC | $44.73 | 2022 | |
| Cequr Corporation | $43.31 | 2023 | Cequr Simplicity |
| Abbvie INC. | $39.70 | 2021 | |
| Nevro Corp. | $30.11 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $30.00 | 2023 | Imcivree |
| Valeritas, INC. | $22.67 | 2019 | |
| Lifescan, INC. | $21.77 | 2022 | |
| Horizon Therapeutics Plc | $20.04 | 2021 | |
| Shire North American Group INC | $19.07 | 2019 | |
| Integra Lifesciences Corporation | $14.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.